Pharmaceuticals, Vol. 11, Pages 105: Evidence for Transient Receptor Potential (TRP) Channel Contribution to Arthritis Pain and Pathogenesis (Pharmaceuticals)

Based on clinical and preclinical evidence, Transient Receptor Potential (TRP) channels have emerged as potential drug targets for the treatment of osteoarthritis, rheumatoid arthritis, and gout. This review summarizes the relevant data supporting a role for various TRP channels in arthritis pain and pathogenesis, as well as the current state of pharmacological efforts to ameliorate arthritis symptoms in patient populations.